WO2003084507A3 - Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen - Google Patents

Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen Download PDF

Info

Publication number
WO2003084507A3
WO2003084507A3 PCT/DE2003/001068 DE0301068W WO03084507A3 WO 2003084507 A3 WO2003084507 A3 WO 2003084507A3 DE 0301068 W DE0301068 W DE 0301068W WO 03084507 A3 WO03084507 A3 WO 03084507A3
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
pulmonary administration
atomizable
active substances
substances
Prior art date
Application number
PCT/DE2003/001068
Other languages
English (en)
French (fr)
Other versions
WO2003084507A2 (de
Inventor
Thomas Schmehl
Tobias Gessler
Esther Waschkowitz
Original Assignee
Univ Giessen Justus Liebig
Thomas Schmehl
Tobias Gessler
Esther Waschkowitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Giessen Justus Liebig, Thomas Schmehl, Tobias Gessler, Esther Waschkowitz filed Critical Univ Giessen Justus Liebig
Priority to AU2003233921A priority Critical patent/AU2003233921A1/en
Priority to EP03727164A priority patent/EP1490026B1/de
Priority to DE50313292T priority patent/DE50313292D1/de
Priority to AT03727164T priority patent/ATE489940T1/de
Priority to US10/510,040 priority patent/US8652512B2/en
Publication of WO2003084507A2 publication Critical patent/WO2003084507A2/de
Publication of WO2003084507A3 publication Critical patent/WO2003084507A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft die Herstellung von spezi­fischen Liposomen zur pulmonalen Applikation von Arzneistof­fen. Die aus den Stoffen DPPC und Cholesterin im molaren Ver­hältnis von 7:3 bzw. 7:4 formulierten Liposomen werden durch nicht-toxische Zusätze wie Sphingomyelin, Dimyristoylphospha­tidylcholin und/oder Polyethylenglykol ergänzt, sind stabil gegenüber Vernebelung mit handelsüblichen Verneblern und wei­sen gleichzeitig eine verzögerte Freisetzungskinetik des Wirkstoffes auf.
PCT/DE2003/001068 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen WO2003084507A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003233921A AU2003233921A1 (en) 2002-04-04 2003-04-01 Atomizable liposomes and their use for the pulmonary administration of active substances
EP03727164A EP1490026B1 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
DE50313292T DE50313292D1 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
AT03727164T ATE489940T1 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
US10/510,040 US8652512B2 (en) 2002-04-04 2003-04-04 Nebulized liposomes for the pulmonary application of drug compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214983.6 2002-04-04
DE10214983A DE10214983A1 (de) 2002-04-04 2002-04-04 Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen

Publications (2)

Publication Number Publication Date
WO2003084507A2 WO2003084507A2 (de) 2003-10-16
WO2003084507A3 true WO2003084507A3 (de) 2004-02-12

Family

ID=28684760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/001068 WO2003084507A2 (de) 2002-04-04 2003-04-01 Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen

Country Status (7)

Country Link
US (1) US8652512B2 (de)
EP (1) EP1490026B1 (de)
AT (1) ATE489940T1 (de)
AU (1) AU2003233921A1 (de)
DE (2) DE10214983A1 (de)
ES (1) ES2356905T3 (de)
WO (1) WO2003084507A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1920765A1 (de) * 2006-11-07 2008-05-14 Medigene AG Single-Pass Verfahren zur Liposomherstellung
BRPI0809852A2 (pt) 2007-03-30 2014-09-23 Hirofumi Takeuchi Lipossoma transpulmonar para controlar a chegada de fármaco
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP2544663B1 (de) 2010-03-12 2018-01-03 Berg LLC Intravenöse formulierung aus dem coenzym q10 (coq10) und verwendungsverfahren dafür
KR102128248B1 (ko) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EA201490047A1 (ru) * 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
DK2968586T3 (en) 2013-03-14 2018-10-08 Translate Bio Inc CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS
WO2015061500A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
KR20210003197A (ko) 2018-04-23 2021-01-11 티엘씨 바이오파머슈티컬즈 인코포레이티드 폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물
KR20210044771A (ko) * 2018-07-02 2021-04-23 압타미르 테라퓨틱스, 인코포레이티드 인간 지방세포에 대한 치료제의 표적화 전달
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (de) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ladung und gesteuerte Abgabe von Molekülen zu und von Liposomen
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
WO2002003959A1 (en) * 2000-07-06 2002-01-17 The General Hospital Corporation Drug delivery formulations and targeting

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732914A (en) * 1978-02-13 1988-03-22 The Upjohn Company Prostacyclin analogs
JPH0768117B2 (ja) 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
WO1986006959A1 (en) * 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
US5340587A (en) * 1985-05-22 1994-08-23 Liposome Technology, Inc. Liposome/bronchodilator method & System
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
SE8601457D0 (sv) * 1986-04-01 1986-04-01 Draco Ab Compositions of liposomes and b?712-receptor active substances for inhalation
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
DK0555229T3 (da) * 1990-07-31 1996-08-19 Liposome Co Inc Akkumulation af aminosyrer og peptider i liposomer
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US20010055610A1 (en) * 1997-06-06 2001-12-27 Shunji Nagata Medicament administration system
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
AU2002323266B2 (en) * 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
CA2457148A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
EP1480691A4 (de) * 2002-03-05 2007-11-28 Univ State Cleveland Agglomerierte teilchen für die abgabe eines arzneimittels in aerosolform
EP1485068A2 (de) * 2002-03-20 2004-12-15 Advanced Inhalation Research, Inc. hGH (MENSCHLICHES WACHSTUMSHORMON) FORMULIERUNGEN ZUR PULMONALEN VERABREICHUNG
AU2003279010A1 (en) * 2002-09-28 2004-04-19 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
JP2006528701A (ja) 2003-05-20 2006-12-21 エリモス・ファーマスーティカルズ・エルエルシー 疾患の治療のためのカテコールブタンの投与のための方法と組成物
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN102697790A (zh) * 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
PL1786490T3 (pl) 2004-07-21 2012-07-31 Animas Corp Sposób i układ dostarczania połączenia urządzenia infuzyjnego
WO2009070609A2 (en) 2007-11-27 2009-06-04 The Board Of Regents Of The University Of Texas System Therapeutic targeting of il-6 using sirna in neutral liposomes
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
WO2009129395A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (de) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ladung und gesteuerte Abgabe von Molekülen zu und von Liposomen
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
WO2002003959A1 (en) * 2000-07-06 2002-01-17 The General Hospital Corporation Drug delivery formulations and targeting

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SINGH M ET AL: "Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 59, no. 1, 1 May 1999 (1999-05-01), pages 43 - 53, XP004166214, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
US8652512B2 (en) 2014-02-18
ES2356905T3 (es) 2011-04-14
AU2003233921A1 (en) 2003-10-20
ATE489940T1 (de) 2010-12-15
US20060002992A1 (en) 2006-01-05
DE50313292D1 (de) 2011-01-13
EP1490026B1 (de) 2010-12-01
WO2003084507A2 (de) 2003-10-16
DE10214983A1 (de) 2004-04-08
EP1490026A2 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2003084507A3 (de) Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
HUP0300188A3 (en) Carboxylic acid derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
WO2007146248A3 (en) Stable laquinimod preparations
MY142029A (en) Phenoxyacetic acid derivatives
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
WO2001032632A3 (en) Pharmaceutically active 4-substituted pyrimidine derivatives
CA2468916A1 (en) A stable oxaliplatin solution formulation
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2004033418A3 (en) Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
ZA9811796B (en) New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them.
IL164699A (en) Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient
WO2004026836A3 (en) 1-pyridin-4-yl-urea derivatives
WO2001010816A3 (de) Substituierte 2-Dialkylaminoalkylbiphenyl-derivate
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
WO2004017943A3 (en) Non-vesicular cationic lipid formulations
WO2002015876A3 (en) Amorphous carrier materials for drug delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN ID JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003727164

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727164

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006002992

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10510040

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10510040

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP